• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    TG Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/3/25 7:19:26 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TGTX alert in real time by email
    tgtx20250225_8k.htm
    false 0001001316 0001001316 2025-03-03 2025-03-03
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): March 3, 2025
     
    TG Therapeutics, Inc.
    (Exact Name of Registrant as Specified in Charter)
     
    Delaware
    001-32639
    36-3898269
    (State or Other Jurisdiction
    (Commission File Number)
    (IRS Employer Identification No.)
    of Incorporation)
    ​
    ​
     ​
    3020 Carrington Mill Blvd, Suite 475
    Morrisville, North Carolina 27560
    (Address of Principal Executive Offices)
     
    (212) 554-4484
    (Registrant’s telephone number, including area code)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities filed pursuant to Section 12(b) of the Act:
     
    Title of Class
    Trading Symbol(s)
    Exchange Name
    Common Stock
    TGTX
    Nasdaq Capital Market
     ​
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     
     

     
     
    Item 2.02. Results of Operations and Financial Condition.
     ​
    On March 3, 2025, the Company issued a press release announcing results of operations for the three and twelve months ended December 31, 2024. A copy of such press release is being furnished as Exhibit 99.1.
     
    In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
     
    Item 9.01. Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit No.
     
    Description
         
    99.1
     
    Press release issued by TG Therapeutics, Inc., dated March 3, 2025.
         
    Exhibit 104
     
    The cover page from this Current Report on Form 8-K formatted in Inline XBRL.
     ​
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    ​
    TG Therapeutics, Inc.
    ​
    (Registrant)
    Date: March 3, 2025
    By:
    /s/ Sean A. Power
    ​
    ​
    Sean A. Power
    ​
    ​
    Chief Financial Officer
     ​
     
    Get the next $TGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TGTX

    DatePrice TargetRatingAnalyst
    10/29/2024$50.00Buy
    TD Cowen
    8/2/2023$16.00 → $12.00Sell → Neutral
    Goldman
    6/26/2023$55.00 → $40.00Buy
    Jefferies
    5/20/2022$5.00Underperform
    BofA Securities
    2/23/2022$49.00 → $35.00Buy
    B. Riley Securities
    1/28/2022$70.00 → $68.00Buy
    HC Wainwright & Co.
    1/24/2022$75.00 → $70.00Buy
    HC Wainwright & Co.
    12/1/2021$55.00 → $36.00Outperform
    Evercore ISI Group
    More analyst ratings

    $TGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on TG Therapeutics with a new price target

      TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00

      10/29/24 6:30:43 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics upgraded by Goldman with a new price target

      Goldman upgraded TG Therapeutics from Sell to Neutral and set a new price target of $12.00 from $16.00 previously

      8/2/23 8:51:11 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on TG Therapeutics with a new price target

      Jefferies resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $40.00 from $55.00 previously

      6/26/23 9:08:22 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025. The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisitio

      6/6/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

      NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, 2025. The fireside chat is scheduled to take place on Wednesday, June 4, 2025, at 12:50 PM ET. A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on

      6/2/25 8:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

      NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to each presentation are included below. "We were pleased to present three encore presentations yesterday during the CMSC conference. We continue to be impressed by the BRIUMVI data and look forward to continuing to present updated data throughout the year."TG PRESENTATIONS:Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections w

      5/30/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

      Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

      10/31/24 4:38:40 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

      Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

      12/28/22 12:54:09 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for UKONIQ

      Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

      2/9/21 12:05:59 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care